moxifloxacin has been researched along with u 100480 in 2 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (u 100480) | Trials (u 100480) | Recent Studies (post-2010) (u 100480) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 43 | 3 | 34 |
| Protein | Taxonomy | moxifloxacin (IC50) | u 100480 (IC50) |
|---|---|---|---|
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
2 review(s) available for moxifloxacin and u 100480
| Article | Year |
|---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |